GlassScriptPhysician profile
Kenneth D Beaty
NPI 1255364782
$3,911.05
in general payments reported to CMS, 2019-2025
29 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $405 · 2021: $821 · 2022: $417 · 2023: $462 · 2024: $816 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.31 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $329.28 | 2019-2022 | |
| Axsome Therapeutics, INC. | $293.89 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $256.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $199.93 | 2020-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $185.03 | 2021-2025 | Vraylar |
| Pfizer INC. | $180.80 | 2020-2024 | |
| Corcept Therapeutics | $171.00 | 2023-2025 | Korlym |
| Abbott Laboratories | $137.09 | 2021-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $123.47 | 2020-2025 | Trintellix |
| Lilly USA, LLC | $121.52 | 2020-2025 | Mounjaro |
| Avanir Pharmaceuticals, INC. | $99.42 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $97.84 | 2020-2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $83.33 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.72 | 2019-2024 | Trulance, Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.66 | 2021-2024 | Ofev |
| Biohaven Pharmaceuticals, INC. | $81.61 | 2021 | |
| Vanda Pharmaceuticals INC. | $72.77 | 2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $57.43 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $47.16 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.04 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $43.32 | 2025 | |
| Jazz Pharmaceuticals INC. | $38.23 | 2024 | |
| Novartis Pharmaceuticals Corporation | $31.12 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $28.54 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.18 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $17.12 | 2020 | |
| Eisai INC. | $14.92 | 2021 | |
| Sumitomo Pharma America, INC. | $13.89 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Beaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.